Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.36 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.36 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3832951 | 0.98 | CYP1A2 (0.58) | CYP1A2CYP2D6TRPA1TRPV1DNM1 | |
| Hydrochloric Acid SCHEMBL28536401 | 0.85 | CYP1A2 (0.51) | CYP1A2CYP2D6DNM1 | |
| Hydrochloric Acid SCHEMBL10619074 | 0.83 | CYP1A2 (0.57) | CYP1A2CYP2D6DNM1ALDH1A1TSHR | |
| SCHEMBL3275536 | 0.81 | CYP1A2 (0.59) | CYP1A2CYP2D6DNM1ALDH1A1TSHR | |
| Hydrochloric Acid SCHEMBL4292279 | 0.80 | CYP1A2 (0.53) | CYP1A2CYP2D6DNM1ALDH1A1TSHR | |
| Hydrochloric Acid SCHEMBL183997 | 0.80 | CYP1A2 (0.53) | CYP1A2CYP2D6DNM1ALDH1A1TSHR | |
| Hydrochloric Acid SCHEMBL3106048 | 0.78 | TRPA1 (0.39) | TRPA1TRPV1 | |
| SCHEMBL1046361 | 0.78 | CYP1A2 (0.55) | CYP1A2CYP2D6ALDH1A1TSHR | |
| Hydrochloric Acid SCHEMBL15158235 | 0.76 | CYP1A2 (0.73) | CYP1A2CYP2D6DNM1 | |
| SCHEMBL3830223 | 0.76 | CYP1A2 (0.82) | CYP1A2CYP2D6DNM1ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110520731-B | Kit, method and reagent for measuring substance to be measured | 富士胶片株式会社 | 2023-04-28 | — | — | CN | disclosed |
| CN-110520732-A | Reagent kit, method and reagent for measuring substance to be measured | FUJIFILM CORP | 2019-11-29 | — | — | CN | disclosed |
| CN-110520731-A | Kit, method and reagent for being measured to measured substance | FUJIFILM CORP | 2019-11-29 | — | — | CN | disclosed |
| US-9980952-B2 | Modulators of methyl modifying enzymes, compositions and uses thereof | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2018-05-29 | — | — | US | disclosed |
| US-20170312262-A9 | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2017-11-02 | — | — | US | disclosed |
| EP-2812001-B1 | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS INC (US) | 2017-06-14 | — | — | EP | disclosed |
| US-20160333016-A1 | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2016-11-17 | — | — | US | disclosed |
| US-9371331-B2 | Modulators of methyl modifying enzymes, compositions and uses thereof | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2016-06-21 | — | — | US | disclosed |
| CN-105188694-A | Sodium channel modulators for the treatment of pain | CHROMOCELL CORP | 2015-12-23 | — | — | CN | disclosed |
| US-20150259351-A1 | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2015-09-17 | — | — | US | disclosed |
| US-9085583-B2 | Modulators of methyl modifying enzymes, compositions and uses thereof | Constellation—Pharmaceuticals, Inc. (US) | 2015-07-21 | — | — | US | disclosed |
| CN-104557906-A | Method for preparing azasetron hydrochloride | SICHUAN HAIRONG PHARMACEUTICAL CO LTD YANGTZE RIVER PHARMACEUTICAL GROUP | 2015-04-29 | — | — | CN | disclosed |
| US-20150011546-A1 | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS, INC. | 2015-01-08 | — | — | US | disclosed |
| CN-103360608-A | Method for preparing comb-like polylactic acid by direct polycondensation | UNIV JIANGNAN | 2013-10-23 | — | — | CN | disclosed |
| US-20090062146-A1 | BIOSENSOR CHIP, PROCESS FOR PRODUCING THE SAME, AND SENSOR FOR SURFACE PLASMON RESONANCE ANALYSIS | FUJIFILM CORPORATION (JP) | 2009-03-05 | — | — | US | disclosed |
| EP-2030677-A2 | Biosensor chip, process for producting the same, and sensor for surface plasmon resonance analysis | FUJIFILM Corporation (JP) | 2009-03-04 | — | — | EP | disclosed |
| EP-0651761-B1 | METHOD FOR MODIFICATION OF RECOMBINANT POLYPEPTIDES | BIONEBRASKA INC (US) | 2002-10-09 | — | — | EP | disclosed |
| EP-1170300-A1 | Method for modification of recombinant polypeptides | BIONEBRASKA, INC. (US) | 2002-01-09 | — | — | EP | disclosed |
| US-5656456-A | Chemical method for selective modification of the N- and/or C-terminal amino acid α-carbon reactive group of a recombinant polypeptide or a portion thereof | BIONEBRASKA, INC. (US) | 1997-08-12 | — | — | US | disclosed |
| US-5635371-A | Chemical method for selective modification of the N- and/or C-terminal amino acid α-carbon reactive group of a recombinant polypeptide or a portion thereof | BIONEBRASKA, INC. (US) | 1997-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170312262-A9 | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF | TET1, TET3, EHMT2 | CYP1A2 1037/4885CYP2D6 1357/4885TRPA1 4877/4885 |
| US-20160333016-A1 | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF | TET1, TET3, EHMT2 | CYP1A2 1037/4885CYP2D6 1357/4885TRPA1 4877/4885 |
| US-20150011546-A1 | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF | TET1, TET3, EHMT2 | CYP1A2 1037/4885CYP2D6 1357/4885TRPA1 4877/4885 |
| US-20150259351-A1 | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF | TET1, TET3, EHMT2 | CYP1A2 1037/4885CYP2D6 1357/4885TRPA1 4877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.